METTL3 and neoplasm: Additionally, Pan and colleagues showed that the m6A writer METTL3 triggers the m6A-SCAP-cholesterol pathway, resulting in the suppression of anti-tumor CD8+ T cells, subsequently facilitating the development of MASLD-HCC [72].